Safety profile of cariprazine: Post hoc analysis of safety parameters of pooled cariprazine schizophrenia studies

被引：1
|
作者：
Szatmari, B. [1 ]
Barabassy, A. [1 ]
Laszlovszky, I. [1 ]
Harsanyi, J. [1 ]
Acsai, K. [1 ]
Burjan, A. [1 ]
Sebe, B. [1 ]
Earley, W. [2 ]
Patel, M. [2 ]
Nemeth, G. [1 ]
机构：
[1] Gedeon Richter Plc, Med Div, Budapest, Hungary
[2] Allergan Pharmaceut Inc, Madison, NJ USA
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2019年 / 29卷
关键词：
D O I：
10.1016/j.euroneuro.2018.11.635
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.618
引用
收藏
页码：S419 / S419
页数：1
相关论文
共 50 条
  • [1] A Pooled Post Hoc Analysis Evaluating the Safety of Cariprazine in Bipolar Depression
    Earley, W.
    Burgess, M.
    Rekeda, L.
    Hankinson, A.
    McIntyre, R. S.
    Suppes, T.
    Calabrese, J.
    Yatham, L. N.
    BIPOLAR DISORDERS, 2019, 21 : 146 - 146
  • [2] The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis
    Nasrallah, Henry A.
    Earley, Willie
    Cutler, Andrew J.
    Wang, Yao
    Lu, Kaifeng
    Laszlovszky, Istvan
    Nemeth, Gyorgy
    Durgam, Suresh
    BMC PSYCHIATRY, 2017, 17
  • [3] The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis
    Henry A. Nasrallah
    Willie Earley
    Andrew J. Cutler
    Yao Wang
    Kaifeng Lu
    István Laszlovszky
    György Németh
    Suresh Durgam
    BMC Psychiatry, 17
  • [4] A pooled post hoc analysis evaluating the safety and tolerability of cariprazine in bipolar depression
    Earley, Willie R.
    Burgess, Maria
    Rekeda, Ludmyla
    Hankinson, Arlene
    McIntyre, Roger S.
    Suppes, Trisha
    Calabrese, Joseph R.
    Yatham, Lakshmi N.
    JOURNAL OF AFFECTIVE DISORDERS, 2020, 263 : 386 - 395
  • [5] Akathisia during cariprazine treatment: Post-hoc analyses of pooled schizophrenia studies
    Barabassy, A.
    Sebe, B.
    Szatmari, B.
    Laszlovszky, I.
    Harsanyi, J.
    Acsai, K.
    Seregi, B.
    Earley, W.
    Patel, M.
    Nemeth, G.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S323 - S323
  • [6] Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies
    Barabassy, Agota
    Sebe, Barbara
    Acsai, Karoly
    Laszlovszky, Istvan
    Szatmari, Balazs
    Earley, Willie R.
    Nemeth, Gyorgy
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2021, 17 : 957 - 970
  • [7] Safety and efficacy of cariprazine in FDA-approved dose ranges for schizophrenia and bipolar I disorder: a pooled post hoc analysis
    Earley, W.
    Durgam, S.
    Lu, K.
    Nemeth, G.
    Edwards, J.
    Laszlovszky, I.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S551 - S551
  • [8] Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis
    Durgam, Suresh
    Earley, Willie
    Lu, Kaifeng
    Nemeth, Gyorgy
    Laszlovszky, Istvan
    Volk, Stephen
    Litman, Robert E.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2017, 71 (12)
  • [9] Metabolic Safety of Cariprazine in Patients with Schizophrenia
    Marder, Stephen
    Zukin, Stephen
    Lu, Kaifeng
    Debelle, Marc
    Durgam, Suresh
    NEUROPSYCHOPHARMACOLOGY, 2015, 40 : S205 - S205
  • [10] Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data
    Earley, Willie
    Guo, Hua
    Daniel, David
    Nasrallah, Henry
    Durgam, Suresh
    Zhong, Yan
    Patel, Mehul
    Barabassy, Agota
    Szatmari, Balazs
    Nemeth, Gyorgy
    SCHIZOPHRENIA RESEARCH, 2019, 204 : 282 - 288
12345